{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:07:24Z","timestamp":1791176844309,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"46","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.vaccine.2011.07.096","type":"journal-article","created":{"date-parts":[[2011,8,4]],"date-time":"2011-08-04T00:30:15Z","timestamp":1312417815000},"page":"8443-8450","source":"Crossref","is-referenced-by-count":176,"title":["The cost-effectiveness of male HPV vaccination in the United States"],"prefix":"10.1016","volume":"29","author":[{"given":"Harrell W.","family":"Chesson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatus U.","family":"Ekwueme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Saraiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen F.","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri E.","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.07.096_bib0005","series-title":"Vaccines for the 21st century: a tool for decisionmaking","author":"Institute of Medicine","year":"2000"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0010","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jnci\/djh104","article-title":"Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine","volume":"96","author":"Goldie","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3201\/eid0901.020168","article-title":"Cost-effectiveness of a potential vaccine for human papillomavirus","volume":"9","author":"Sanders","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0020","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.290.6.781","article-title":"Potential health and economic impact of adding a human papillomavirus vaccine to screening programs","volume":"290","author":"Kulasingam","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0025","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3201\/eid1011.040222","article-title":"Evaluating human papillomavirus vaccination programs","volume":"10","author":"Taira","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0030","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0035","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3201\/eid1402.070499","article-title":"Cost-effectiveness of human papillomavirus vaccination in the United States","volume":"14","author":"Chesson","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0040","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMsa0707052","article-title":"Health and economic implications of HPV vaccination in the United States","volume":"359","author":"Kim","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0045","doi-asserted-by":"crossref","first-page":"b3884","DOI":"10.1136\/bmj.b3884","article-title":"Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States","volume":"339","author":"Kim","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0050","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","article-title":"Impact of vaccinating boys and men against HPV in the United States","volume":"28","author":"Elbasha","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0055","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000214924","article-title":"Economic evaluation of human papillomavirus vaccination in developed countries","volume":"12","author":"Brisson","year":"2009","journal-title":"Public Health Genomics"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0060","doi-asserted-by":"crossref","first-page":"a769","DOI":"10.1136\/bmj.a769","article-title":"Economic evaluation of human papillomavirus vaccination in the United Kingdom","volume":"337","author":"Jit","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0065","doi-asserted-by":"crossref","unstructured":"FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915\u201327.","DOI":"10.1056\/NEJMoa061741"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0070","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0075","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0080","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24\u201345 years: a randomised, double-blind trial","volume":"373","author":"Munoz","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0085","series-title":"European Research Organization on Genital Infection and Neoplasia (EUROGIN Conference 2008)","article-title":"Efficacy of the quadrivalent HPV vaccine against HPV 6\/11\/16\/18-related genital infection in young men","author":"Palefsky","year":"2008"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0090","series-title":"European Research Organization on Genital Infection and Neoplasia (EUROGIN Conference 2008)","article-title":"The efficacy of quadrivalent HPV (types 6\/11\/16\/19) vaccine in reducing the incidence of HPV-related genital disease in young men","author":"Guiliano","year":"2008"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0095","first-page":"997","article-title":"National, state, and local area vaccination coverage among adolescents aged 13\u201317 years \u2013 United States, 2008","volume":"58","author":"Stokley","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"August (32)","key":"10.1016\/j.vaccine.2011.07.096_bib0100","first-page":"1018","article-title":"National, state, and local area vaccination coverage among adolescents aged 13\u201317 years \u2013 United States, 2009","volume":"59","author":"Dorell","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0105","series-title":"Meeting of the Advisory Committee on Immunization Practices","article-title":"HPV vaccine session background","author":"Markowitz","year":"2011"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0110","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/14737167.8.2.165","article-title":"Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold","volume":"8","author":"Grosse","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"9719","key":"10.1016\/j.vaccine.2011.07.096_bib0115","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(09)62029-8","article-title":"Gardasil: from bench, to bedside, to blunder","volume":"375","author":"Bach","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0120","doi-asserted-by":"crossref","first-page":"s23","DOI":"10.1097\/01.gco.0000216317.10690.8f","article-title":"Understanding and overcoming barriers to human papillomavirus vaccine acceptance","volume":"18","author":"Zimet","year":"2006","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0125","first-page":"S484","article-title":"Overcoming barriers to adherence to HPV vaccination recommendations","volume":"12","author":"Dempsey","year":"2006","journal-title":"Am J Manag Care"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2011.07.096_bib0130","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/j.vaccine.2006.05.116","article-title":"Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes","author":"Garnett","year":"2006","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.vaccine.2011.07.096_bib0135","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1016\/j.vaccine.2010.05.056","article-title":"Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis","volume":"28","author":"Van de Velde","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0140","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0145","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0150","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ajog.2004.01.043","article-title":"Diagnoses and outcomes in cervical cancer screening: a population-based study","volume":"191","author":"Insinga","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0155","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1071\/SH07043","article-title":"A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program","volume":"4","author":"Kulasingam","year":"2007","journal-title":"Sex Health"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0160","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0272989X07302128","article-title":"Abnormal outcomes following cervical cancer screening: event duration and health utility loss","volume":"27","author":"Insinga","year":"2007","journal-title":"Med Decis Making"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0165","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1185\/03007990903136378","article-title":"Assessing incidence and economic burden of genital warts with data from a US commercially insured population","volume":"25","author":"Hoy","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0170","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ajog.2008.03.064","article-title":"The economic burden of noncervical human papillomavirus disease in the United States","volume":"198","author":"Hu","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0175","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/OLQ.0b013e3181a74c2c","article-title":"Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom","volume":"36","author":"Woodhall","year":"2009","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0180","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ygyno.2008.07.032","article-title":"Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan","volume":"111","author":"Insinga","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0185","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1086\/313914","article-title":"Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle","volume":"31","author":"Armstrong","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2011.07.096_bib0190","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1016\/j.vaccine.2008.06.045","article-title":"The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination","volume":"26","author":"Chesson","year":"2008","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11011467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11011467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T23:53:04Z","timestamp":1543621984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11011467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":38,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0264410X11011467"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.07.096","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}